Myeloma UK participates in first Oxford Myeloma Workshop

Myeloma UK news, Patient advocacy news, Research news // 25th August 2017

This August, Myeloma UK attended the first Oxford Myeloma Workshop, a two day event for scientists and healthcare professionals including doctors and specialist nurses, which provided insight into developments in the scientific understanding of myeloma, diagnostic testing and treatment options for patients.

Myeloma UK attends a number of key workshops and scientific meetings throughout the year. Attendance at these meetings helps us to gain insight into current research into myeloma, and importantly, to look at how we can continue to innovate and improve treatment and care for patients. Alongside informing our work, these events also provide us with the opportunity to knowledge share and network with the wider myeloma community.

Organised by Dr Karthik Ramasamy, Prof Udo Oppermann and Dr Jaimal Kotharim, this Workshop had a clear theme that centred on collaboration. It highlighted the importance of collaboration among healthcare professionals, researchers, pharmaceutical companies, policy makers and patients to be able to diagnose myeloma earlier, overcome scientific hurdles in understanding the biology of myeloma, discover new treatment targets and develop treatments, and improve knowledge on what patients want and need.

The Workshop featured a panel of distinguished international speakers including Kenneth Anderson whose plenary lecture highlighted how research into new treatments for myeloma, such as immunotherapy, has significantly increase treatment options for myeloma patients in recent years. He also gave an overview of current research that is taking place to discover more targeted approaches to treating myeloma.

Myeloma UK was pleased to take part in two round table discussions that played an important role in the meeting by bringing the faculty together to discuss current issues in myeloma.

Our CEO, Rosemarie Finley, participated in the first panel debate which discussed how and when myeloma might be cured. Rosemarie highlighted important issues during the discussion including the need to develop our understanding of what matters to patients in terms of their treatment and care, and how we can improve quality of life for all patients. She also underlined the importance of educating healthcare professionals to assist with earlier diagnosis and importantly managing myeloma well.

Rosemarie said, “This event was a great opportunity to shine a light on the work that we do at Myeloma UK, and how we can help to drive research forward. Events like this are important as they help to support the education of healthcare professionals.”

This event was a great opportunity to shine a light on the work that we do at Myeloma UK, and how we can help to drive research forward. Events like this are important as they help to support the education of healthcare professionals.

CEO, Rosemarie Finley

Dr Simon Ridley, Director of Research at Myeloma UK, took part in a panel discussion which focused on relapsed myeloma, and the challenges of managing patients with treatment resistant and genetically complex myeloma. He highlighted the vital work of the Myeloma UK Clinical Trial Network, which is focused on gaining a better understanding of the treatments or combination of treatments that are best for patients at different stages of myeloma, and to look at how new treatments may be made available to patients in the UK. He also underlined how important it is to have good and honest communication between patients and their medical teams.

Throughout the Workshop, staff from Myeloma UK also engaged with attendees to raise awareness of the information and support services we provide to patients, and our education programme for healthcare professionals, Myeloma Academy.

Find out more about what we do, and how you can support our work here.